Less artificial…more intelligence
In the industry of clinical research, we are accustomed to working with conservative companies that make decisions slowly. Look at the adoption of EDC – over how many decades now? Understandable, at least to a point.
Filling the tech gap in metastatic breast cancer clinical trials
According to the American Cancer Society (ACS), a woman living in the United States has a 1 in 8 chance of developing breast cancer, the second-leading cause of cancer death in women (behind only lung cancer).
Site, investigator, or investigator site?
The life sciences industry is riddled with casually used terms, acronyms and phrases which are often used out of context or defined differently among companies or individuals.
Kols: an endangered buzzword
The term, “key opinion leader” (supported by its well-known acronym KOL) is one of the industry’s most common buzzwords, and for good reason.